BioRestorative Therapies (NASDAQ:BRTX) CEO Lance Alstodt and Dr Jason Lipetz, Chief of Spine Medicine at Northwell Health Spine Center and Member of the company’s Scientific Advisory Board joined Steve Darling from Proactive to share news the company is beginning a Phase 2 clinical trial using autologous hypoxic bone marrow-derived stem cells targeted to treat chronic lumbar disc disease. Dr. Lipetz talked about BRTX-100 and what he sees as the difference with this product and other traditional therapies for lumbar pain and injury. Alstodt told Proactive more about the company and its verticals including a cell-based therapy candidate to target obesity and metabolic disorders.
BioRestorative Therapies underway with Phase 2 clinical trial on stem cell-based BRTX-100
